Combination therapy for returning multiple myeloma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called inobrodib combined with two standard treatments (pomalidomide and dexamethasone) for people whose multiple myeloma has come back or did not respond. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with multiple myeloma, and your disease has come back or did not respond to your last treatment.
- You are able to care for yourself (fully active or limited but up and about more than half the day).
- Your blood counts, kidney, and liver function are within acceptable levels.
- You have not taken certain cancer drugs (including experimental ones) in the last 14 days or within a certain time based on the drug's half-life.
- You have never been treated with a drug called a p300/CBP bromodomain inhibitor (like inobrodib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination, inobrodib plus pomalidomide and dexamethasone, in people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this combination works better than the standard available treatments.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This trial tests a new combination of two medicines (etentamig and pomalidomide) against standard treatments for people whose multiple myeloma has returned or not responded to therapy. The goal is to see if this combination works better and is safe.
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This study tests a new combination of drugs for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if the combination helps control the disease.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.